Goldman Sachs Group, Inc. (The) set a CHF 80 price objective on Novartis AG (VTX:NOVN) in a report released on Tuesday morning. The brokerage currently has a neutral rating on the stock.

A number of other analysts also recently issued reports on the stock. Baader Bank set a CHF 90 price target on shares of Novartis AG and gave the company a buy rating in a report on Friday, August 4th. Morgan Stanley set a CHF 88 price objective on shares of Novartis AG and gave the stock a buy rating in a research note on Wednesday, July 26th. Jefferies Group LLC set a CHF 97 price objective on shares of Novartis AG and gave the stock a buy rating in a research note on Monday, July 24th. JPMorgan Chase & Co. set a CHF 75 price objective on shares of Novartis AG and gave the stock a neutral rating in a research note on Wednesday, July 19th. Finally, Societe Generale set a CHF 91 price objective on shares of Novartis AG and gave the stock a buy rating in a research note on Wednesday, July 19th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of CHF 84.60.

Shares of Novartis AG (VTX NOVN) opened at 79.90 on Tuesday. The company has a market cap of CHK 187.20 billion and a price-to-earnings ratio of 29.17. The firm has a 50-day moving average of CHK 81.04 and a 200 day moving average of CHK 77.39. Novartis AG has a 12 month low of CHK 67.40 and a 12 month high of CHK 84.35.

ILLEGAL ACTIVITY NOTICE: “Novartis AG (VTX:NOVN) Given a CHF 80 Price Target by Goldman Sachs Group, Inc. (The) Analysts” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/08/12/novartis-ag-vtxnovn-given-a-chf-80-price-target-by-goldman-sachs-group-inc-the-analysts.html.

Novartis AG Company Profile

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis AG (VTX:NOVN)

Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.